HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast c...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Miller, Kathy, Cortes, Javier, Hurvitz, Sara A., Krop, Ian E., Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G., Wickham, Thomas J., Molnar, Istvan, Yardley, Denise A.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Study Protocol
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893300/
https://ncbi.nlm.nih.gov/pubmed/27259714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2385-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы